Tin tức & Cập nhật

Vitamin K may shield against pancreatic cancer

20 May 2021

Dietary intakes of phylloquinone and dihydrophylloquinone appear to yield a beneficial effect on the risk of developing pancreatic cancer, a study reports.

Vitamin K may shield against pancreatic cancer

20 May 2021

$Decitabine plus camrelizumab shows activity against relapsed, refractory cHL$

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

20 May 2021

Treatment with the combination of decitabine plus camrelizumab yields high response rates and long-term benefits in patients with relapsed/refractory classical Hodgkin lymphoma (cHL) who failed programmed death-1 (PD-1) inhibitors, as shown in a study.

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

20 May 2021

Lymphovascular invasion, higher nodal stage predict recurrence, breast cancer-related deaths

19 May 2021 bởi

The presence of lymphovascular emboli and higher nodal stage (N2 or higher) in a breast carcinoma with medullary-like features are pathologic parameters that are predictive of its possible aggressive and fatal behaviour, a Singapore study suggests.

Lymphovascular invasion, higher nodal stage predict recurrence, breast cancer-related deaths

19 May 2021

Blood loss, liver failure predict survival after surgery in hepatocellular cancer

19 May 2021 bởi

A Singapore study suggests that doctors who want to predict postoperative mortality in hepatocellular carcinoma (HCC) patients after hepatic resection should look at the following: intraoperative blood loss, Child-Pugh score, posthepatectomy liver failure (PLHF), and peak serum bilirubin.

Blood loss, liver failure predict survival after surgery in hepatocellular cancer

19 May 2021

Fluzoparib shows promising activity against BRCA-mutant relapsed ovarian cancer

18 May 2021

The poly(ADP-ribose) polymerase (PARP) inhibitor fluzoparib appears to work in the treatment of patients with germline BRCA1/2-mutated, platinum-sensitive relapsed ovarian cancer, with an acceptable safety profile, as shown in a phase II trial.

Fluzoparib shows promising activity against BRCA-mutant relapsed ovarian cancer

18 May 2021

$Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat$

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

17 May 2021 bởi

In the treatment of patients with radioiodine-refractory thyroid carcinoma, lenvatinib may improve their chances of survival but at the cost of a high adverse event rate, according to the results of a meta-analysis.

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

17 May 2021

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021 bởi

The anti-PD-1 antibody tislelizumab may help improve patient outcomes vs docetaxel as second- or third-line treatment for advanced or metastatic non–small-cell lung cancer (NSCLC) regardless of histology or PD-L1 expression, interim findings from the phase III RATIONALE 303 study have shown.

Tislelizumab trumps docetaxel in pre-treated NSCLC

17 May 2021

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021 bởi

First-line treatment with the bispecific fusion protein tebentafusp demonstrated an overall survival (OS) benefit in patients with human leukocyte antigen (HLA)-A*02:01-positive metastatic uveal melanoma (mUM), according to a phase III, open-label trial presented at AACR 2021.

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

15 May 2021

Beta-1 selective blockers linked to breast cancer risk

15 May 2021

Women using beta-1 selective blockers may be at increased risk of developing breast cancer, with the association showing a dose-response pattern, according to a study.

Beta-1 selective blockers linked to breast cancer risk

15 May 2021

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?

14 May 2021 bởi

In individuals with resected oesophageal or gastro-oesophageal junction (GEJ) cancer who have received neoadjuvant chemoradiotherapy (CRT), adjuvant nivolumab therapy demonstrated superior efficacy over placebo, according to the CheckMate 577 trial.

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?

14 May 2021

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Vitamin K may shield against pancreatic cancer

Vitamin K may shield against pancreatic cancer

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

Decitabine plus camrelizumab shows activity against relapsed, refractory cHL

Lymphovascular invasion, higher nodal stage predict recurrence, breast cancer-related deaths

Lymphovascular invasion, higher nodal stage predict recurrence, breast cancer-related deaths

Blood loss, liver failure predict survival after surgery in hepatocellular cancer

Blood loss, liver failure predict survival after surgery in hepatocellular cancer

Fluzoparib shows promising activity against BRCA-mutant relapsed ovarian cancer

Fluzoparib shows promising activity against BRCA-mutant relapsed ovarian cancer

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

Meta-analysis: Lenvatinib boosts survival in refractory thyroid carcinoma with caveat

Tislelizumab trumps docetaxel in pre-treated NSCLC

Tislelizumab trumps docetaxel in pre-treated NSCLC

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

First-line tebentafusp may extend OS in HLA-A*02:01-positive metastatic uveal melanoma

Beta-1 selective blockers linked to breast cancer risk

Beta-1 selective blockers linked to breast cancer risk

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?

Adjuvant nivolumab: a new SoC for resected oesophageal or GEJ cancer?